Helius to Enhance Hughes' Business IPTV and Managed Network Service Offerings

Hughes Communications, Inc. (HUGHES), the global leader in broadband satellite network solutions and a leading broadband managed network services provider, announced today that it has entered into a definitive agreement to acquire Helius, Inc., a portfolio company of Canopy Ventures.

The acquisition is expected to be completed on or about February 4, 2008.

Upon completion of the acquisition, Helius will become a wholly owned subsidiary of Hughes and will operate closely with Hughes' North America and International enterprise businesses.

CALGARY, Canada, January 4 /PRNewswire/ -- Tristone Capital is pleased to announce the initiation of equity research coverage on Schlumberger (SLB), Halliburton (HAL), and Baker Hughes (BHI). Coverage will be led by Waqar Syed, Vice President & Director, Institutional Research, based in Tristone's Denver office. Mr. Syed began his 20 year career in the oil and gas industry as a wireline engineer with Schlumberger in the Middle East and has worked as an energy research analyst for 14 years. Mr. Syed was ranked as the No. 1 earnings forecaster in the energy sector by StarMine in 2007 and was the No. 4 overall earnings forecaster among all research analysts across all sectors.

COPENHAGEN, January 4 /PRNewswire/ --

- Summary: Genmab Has Announced a New Pre-clinical Antibody Program Called HuMax-CD32b.

Genmab A/S (OMX: GEN) announced today a new pre-clinical antibody program called HuMax-CD32b(TM). This fully human IgG1,k antibody targets the CD32b receptor found on immune cells and hematological tumors. HuMax-CD32b may have therapeutic potential in the treatment of B-cell chronic lymphocytic leukemia, small lymphocytic lymphoma, Burkitt's lymphoma, follicular lymphoma and diffuse large B-cell lymphoma.

ATLANTA, January 3 /PRNewswire/ --

Global Payments Inc. (NYSE: GPN) today announced results for its second quarter ended November 30, 2007. For the second quarter, revenue grew 18 percent to US$308.8 million compared to US$260.7 million in the prior year. Excluding the impact of current period restructuring charges, diluted earnings per share grew 14 percent to US$0.48 compared to US$0.42 in the prior year quarter.

(Logo: http://www.newscom.com/cgi-bin/prnh/20010221/ATW031LOGO )

LUGANO, Switzerland, January 3 /PRNewswire/ -- Helsinn Healthcare S.A., Switzerland, a privately owned pharmaceutical group and its partner, MGI Pharma (Nasdaq: MOGN), a biopharmaceutical company focused in oncology and acute care, today announced that a supplemental New Drug Application (sNDA) for Aloxi(R) (palonosetron hydrochloride) Capsules for oral administration was accepted for filing by the U.S. Food and Drug Administration (FDA). Aloxi Injection is approved by the FDA for the prevention of acute nausea and vomiting associated with initial and repeat courses of moderately and highly emetogenic cancer chemotherapy and for the prevention of delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy.

CAMBRIDGE, Massachusetts, January 3 /PRNewswire/ --

Mersana, a cancer therapeutics company, announced today the appointment of C. Boyd Clarke as Chairman of the Company's Board of Directors. Mr. Clarke is a senior biotechnology and pharmaceutical executive with a significant record of accomplishment over a 30-year industry career.